News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
News
Drug Development
Merck KGaA Starts New Phase III Trial on MS Pill
September 18, 2008
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LONDON, Sept 18 (Reuters) - Germany's Merck KGaA is launching a new late-stage Phase III clinical trial of its experimental multiple sclerosis pill cladribine, marking a step-up in investment for the product.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase III
Europe
MORE ON THIS TOPIC
Neuroscience
Epilepsy Biotech Nabs up to $570M in Deal With Italy’s Angelini Plus $140M Fundraising
May 27, 2025
·
1 min read
·
Annalee Armstrong
Gene therapy
Rocket’s Danon Disease Gene Therapy on Hold After Patient Death
May 27, 2025
·
2 min read
·
Tristan Manalac
Funding
Karuna, Naurex Alumni Launch New Biotech
to Modulate Synaptic Plasticity for Neuro Diseases
May 27, 2025
·
3 min read
·
Heather McKenzie
Rare diseases
Prothena Looks at Business Options as Phase III AL Amyloidosis Trial Fails
May 27, 2025
·
2 min read
·
Tristan Manalac
